VIR-5500
Asset
Dual-masked T-cell engager targeting PSMA and CD3 to direct T cells to prostate cancer cells
- Stage
- Phase 1
- Modality
- Antibody
- Target
- CD3E
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Metastatic castration-resistant prostate cancer
Phase 1, businesswire.com, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Evidence for its targets2
- Competitors4
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.